Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis
Frontiers in Immunology · 05.06.2026 · 17
DOI: 10.3389/fimmu.2026.1817671 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Frontiers in Immunology, online erschienen am 05.06.2026. Verfasst von Sophie Buhelt und 7 weiteren Autor:innen. Beteiligte Einrichtung: Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark. Hauptthemen laut MEDLINE: Natalizumab, Multiple Sclerosis, Relapsing-Remitting, Inflammation, Immunologic Factors. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and objectives Natalizumab (NTZ) is a high-efficacy therapy for relapsing-remitting multiple sclerosis (RRMS) that blocks peripheral immune cell migration into the central nervous system. While short-term NTZ treatment reduces cerebrospinal fluid (CSF) inflammation, the extent of residual intrathecal inflammation after long-term NTZ treatment and its association with oligoclonal band (OCB) status remains unclear. In this study, we examined associations between NTZ treatment duration, OCB status and CSF inflammatory and tissue biomarkers as well as presence of residual intrathecal inflammation after more than five years of NTZ treatment.
Methods
In this cross-sectional observational study, fifteen inflammatory and tissue biomarkers were reliably measured in CSF using validated immunoassays or extracted from clinical records of 88 NTZ-treated RRMS and 104 untreated RRMS patients as well as 94 controls.
Results
Compared to untreated RRMS patients, most CSF biomarkers were significantly lower in NTZ-treated and controls (Bonferroni-adjusted p (adj-p) < 0.05). However, soluble B cell maturation antigen (sBCMA), soluble CD27 (sCD27), chitotriosidase-1 (CHIT1), IgG index and interleukin-10 (IL-10) were higher in NTZ-treated compared to controls (adj-p < 0.05). NTZ treatment duration was inversely associated with sCD27 levels, and a positive OCB status was associated with higher sCD27 and IgG index (adj-p < 0.05). In patients treated with NTZ for more than five years (n = 41), levels of sCD27, IgG index and sBCMA were higher in OCB-positive patients (adj-p < 0.05), but not in OCB-negative, compared to age-matched controls.
Discussion
Natalizumab treatment reduces CSF inflammation biomarkers, but after more than five years of treatment levels of sCD27, sBCMA and IgG index remain significantly above control levels in OCB-positive NTZ-treated patients. This indicates residual intrathecal adaptive immune activation in OCB-positive NTZ-treated RRMS patients, suggesting that compartmentalized adaptive inflammation in RRMS is incompletely suppressed by NTZ.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark.
Zitieren
APA
Buhelt, S., Hansen, M. B., Søndergaard, H. B., El Mahdaoui, S., Hansen, M. M., Mahler, M. R., Romme Christensen, J., & Sellebjerg, F. (2026). Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1817671
Vancouver
Buhelt S, Hansen MB, Søndergaard HB, El Mahdaoui S, Hansen MM, Mahler MR, et al. Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1817671
BibTeX
@article{Buhelt2026,
author = {Buhelt, Sophie and Hansen, Malene Bredahl and Søndergaard, Helle Bach and El Mahdaoui, Sahla and Hansen, Marie Mathilde and Mahler, Mie Reith and Romme Christensen, Jeppe and Sellebjerg, Finn},
title = {Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.1817671}
}
EUVIMED